⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CYTK News
Cytokinetics Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Stockholders to Connect
accessnewswire.com
CYTK
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com
CYTK
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation
accessnewswire.com
CYTK
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation
accessnewswire.com
CYTK
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Investors to Reach Out
accessnewswire.com
CYTK
Cytokinetics to Participate in March Investor Conferences
globenewswire.com
CYTK
Form 8-K
sec.gov
CYTK
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
CYTK
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
globenewswire.com
CYTK
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
globenewswire.com
CYTK